argenx

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

Breda, the Netherlands – October 8 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced the presentation of additional data from the Phase 3 ADAPT trial of efgartigimod for the treatment of generalized myasthenia gravis (gMG). The data will be presented at two upcoming neuromuscular meetings: the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting on October 13-16, 2021 in Aurora, CO and the virtual Myasthenia Gravis Foundation of America Scientific Session (MGFA) on October 30, 2021.

argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings

Breda, the Netherlands – August 2 5 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it has submitted, and the European Medicines Agency (EMA) has validated, the marketing authorization application (MAA) for the Company's investigational FcRn antagonist, efgartigimod, for the treatment of generalized myasthenia gravis (gMG). Validation of the MAA confirms that the application is sufficiently complete to begin the formal review process.

argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis

argenx held an R&D day last month and it went largely unnoticed. The company outlined an ambitious 2025 vision for efgartigimod, ARGX-117, and its Immunology Innovation Program.

argenx: R&D Day Goes Unnoticed

August 4, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in a fireside chat at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Wednesday, August 11, 2021 at 11:30 a.m. ET.

argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2021 Results - Earnings Call Transcript

Shares of argenx (NASDAQ:ARGX) decreased 4.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 162.86% over the past year to $1.98, which may not compared to the estimate of ($3.63).

Recap: argenx Q2 Earnings

- Completion of enrollment expected by year-end for ADAPT-SC and ADVANCE (IV) trials of efgartigimod; topline data for both trials expected in first half of 2022

argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update

July 22, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, July 29, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2021 financial results and provide a second quarter business update.

argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021

July 14, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a virtual R&D Day on Tuesday, July 20, 2021 at 3:00 p.m. CET (9:00 a.m. ET) to highlight its ‘argenx 2025 vision' and provide an update of its immunology pipeline. The event will introduce the fifth and sixth indications for the Company's FcRn antagonist, efgartigimod, and will include Phase 1 data from its C2 inhibitor, ARGX-117.

argenx to Host Virtual R&D Day on July 20, 2021

One of argenx's main competitors, Immunovant, suffered clinical setbacks this year and these setbacks have further solidified efgartigimod's potential best-in-class position. argenx to become a commercial-stage company by late-2021 with expected efgartigimod approval for generalized myasthenia gravis.

argenx: Next Phase Of Growth With Efgartigimod And ARGX-117

Results from ADAPT showed treatment with efgartigimod provided clinically meaningful improvement s in strength and quality of life measures in g eneralized m yasthenia g ravis (gMG )

argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology

The company's main selling point is a drug called efgartigimod, which the company is testing in six different diseases.

Argenx Is a Biotech Stock With Big Potential

argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate.

argenx (ARGX) to Regain AML Candidate After J&J's Dismissal

Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting cusatuzumab. The pair first came together to develop the med across various blood cancers and disorders in December 2018.

Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab

argenx to regain global rights to cusatuzumab

June 1, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced the appointment of Mr. Karl Gubitz as Chief Financial Officer. Mr. Gubitz brings to argenx nearly 20 years of global pharmaceutical leadership experience, specifically in financial planning and analysis, business partnerships and product commercialization. He will succeed Eric Castaldi, who will remain with the company through June 30, 2021.

argenx Appoints Karl Gubitz as Chief Financial Officer

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2021 Results - Earnings Call Transcript

Shares of argenx (NASDAQ:ARGX) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 60.68% year over year to ($0.81), which may not compare to the estimate of ($3.13).

Recap: argenx Q1 Earnings

Japanese Marketing Authorization Application (J-MAA) for efgartigimod accepted for review by Japan's Pharmaceuticals and Medical Device Agency (PMDA) for generalized myasthenia gravis (gMG)

argenx Reports First Quarter 2021 Financial Results and Provides Business Update

argenx (NASDAQ:ARGX) releases its next round of earnings this Friday, May 14. Here is Benzinga's essential guide to argenx's Q1 earnings report.

argenx's Earnings Outlook

May 7, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Friday, May 14, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2021 financial results and provide a business update.

argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021

April 28, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in the following upcoming conferences:

argenx Management to Present at Upcoming Virtual Investor Conferences

argenx announces Annual General Meeting of Shareholders on May 11, 2021

Biohaven Pharmaceutical Hld

BioMarin Pharmaceutical

Mirati Therapeutics

Novo Nordisk

Novartis

Pharmaceutical stocks are a sector with unique success factors. One factor is developing blockbuster drugs.

7 Pharmaceutical Stocks Working on Their Next Blockbuster

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2020 Results - Earnings Call Transcript

News for argenx Stock (ARGX)